A Longitudinal Observational Cohort Study to Assess Sustained Immunogenicity up to 48 Months to Quadrivalent Human Papillomavirus Vaccine Among HIV-infected Girls and Boys Age 9-14 Years in Kenya.

Trial Profile

A Longitudinal Observational Cohort Study to Assess Sustained Immunogenicity up to 48 Months to Quadrivalent Human Papillomavirus Vaccine Among HIV-infected Girls and Boys Age 9-14 Years in Kenya.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Human papillomavirus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 05 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 27 Oct 2015 Status changed from active, no longer recruiting to recruiting, according to ClinicalTrials.gov record.
    • 21 Mar 2015 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top